Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia

Marco Cerrano, Barbara Castella, Giuseppe Lia, Matteo Olivi, Danilo G Faraci, Sara Butera, Federica Martella, Matilde Scaldaferri, Francesco Cattel, Mario Boccadoro, Massimo Massaia, Dario Ferrero, Benedetto Bruno, Luisa Giaccone, Marco Cerrano, Barbara Castella, Giuseppe Lia, Matteo Olivi, Danilo G Faraci, Sara Butera, Federica Martella, Matilde Scaldaferri, Francesco Cattel, Mario Boccadoro, Massimo Massaia, Dario Ferrero, Benedetto Bruno, Luisa Giaccone

No abstract available

Keywords: T acute lymphoblastic leukaemia; acute leukaemia; daratumumab; immunomodulation; immunotherapy.

References

    1. Bride KL, Vincent TL, Im S-Y, Aplenc R, Barrett DM, Carroll WL, et al. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. Blood. 2018;131:995-9.
    1. Vogiatzi F, Winterberg D, Lenk L, Buchmann S, Cario G, Schrappe M, et al. Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. Blood. 2019;134:713-6.
    1. Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, et al. CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia. Haematologica. 2019;104:e100-3.
    1. Bonda A, Punatar S, Gokarn A, Mohite A, Shanmugam K, Nayak L, et al. Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy? Bone Marrow Transplant. 2018;53:1487-9.
    1. Ofran Y, Ringelstein-Harlev S, Slouzkey I, Zuckerman T, Yehudai-Ofir D, Henig I, et al. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia. Leukemia. 2020;34:293-5.
    1. Mirgh S, Ahmed R, Agrawal N, Khushoo V, Garg A, Will FS, et al. Daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol. 2019;187: .
    1. van de Donk NWCJ. Immunomodulatory effects of CD38-targeting antibodies. Immunol Lett. 2018;199:16-22.
    1. Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384-94.
    1. Chiaretti S, Messina M, Starza ID, Piciocchi A, Cafforio L, Cavalli M, et al. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica. 2020. [Epub ahead of print].
    1. Plesner T, Krejcik J. Daratumumab for the treatment of multiple myeloma. Front Immunol. 2018;9:1228.
    1. Lia G, Di Vito C, Cerrano M, Brunello L, Calcaterra F, Tapparo M, et al. Extracellular vesicles after allogeneic hematopoietic cell transplantation: emerging role in post-transplant complications. Front Immunol. 2020;11. .
    1. Ghose J, Viola D, Terrazas C, Caserta E, Troadec E, Khalife J, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7:e1486948.
    1. Morandi F, Marimpietri D, Horenstein AL, Bolzoni M, Toscani D, Costa F, et al. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD. Oncoimmunology. 2018;7:e1458809.
    1. Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018;131:1522-31.
    1. Yang K, Xu J, Liu Q, Li J, Xi Y. Expression and significance of CD47, PD1 and PDL1 in T-cell acute lymphoblastic lymphoma/leukemia. Pathol Res Pract. 2019;215:265-71.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다